Breo Ellipta (fluticasone furoate and vilanterol), an inhalation powder used for the treatment of COPD, was the first Ellipta inhaler to become available back in 2013. Over the past two years or so, several more Ellipta options have entered the market.
Ellipta medications tend to be a bit more expensive, but some people prefer them to more traditional types of inhalers.
So, what is unique about the Ellipta device?
The Ellipta from GlaxoSmithKline (GSK) is their new platform inhalation device. It has dual strips inside the mechanism, which mix within the device on actuation (when you use the inhaler). The Ellipta differs from the current Diskus device, which only uses 1 inhalation strip.
According to GSK the Ellipta device will better optimize the two medicines that are contained within the inhaler.
Is there an advantage to using the ELLIPTA device?
Yes. Studies on ELLIPTA show that patients prefer it over the Diskus inhalers due to the ease of use, the dose-counter, and the feel and fit of the device.
Which other Ellipta inhalers are on the market?
In addition to Breo Ellipta, Anoro Ellipta (umeclidinium and vilanterol) and Incruse Ellipta (umeclidinium) are available for the treatment of COPD. Another device, Arnuity Ellipta (fluticasone furoate), is available for the treatment of asthma.